Early Use of Biologics Reduces Healthcare Costs in Crohn's Disease: Results from a United States Population-Based Cohort.

Ryan C UngaroApril N NaegeliCasey Kar-Chan ChoongMingyang ShanXianming Steve ZhengTheresa Hunter GibbleKathy OneacreJean-Frederic Colombel

Published in: Digestive diseases and sciences (2023)

While biologic treatments are costly, patients initiating biologics sooner after diagnosis appear to have better HCRU outcomes and require fewer healthcare resources at 1-2 years post-index, potentially leading to overall cost savings.

Keyphrases

healthcare
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
rheumatoid arthritis
prognostic factors
type diabetes
adipose tissue
insulin resistance
health insurance